secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001140361-23-037887
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis and Novartis expand Lp(a) collaboration; Ionis gets $60M upfront for next-gen therapy
--------------------------------------------------------------------------------

- Ionis receives $60 million upfront from Novartis for next-generation Lp(a) compound.
- Builds on existing pelacarsen collaboration; Novartis to handle development and commercialization.
- Agreement subject to HSR antitrust clearance.
- Ionis eligible for additional milestone payments and tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/0001140361-23-037887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123037887/brhc20056974_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-037887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer